Neuroinflammation

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

2 weeks ago talkbio0Tagged Autoimmune, cardiometabolic, Eli, Eli Lilly, Immunotherapy for cancer, InduPro * *, Inflammatory disorder, M&A, Neoplasms, Neuroinflammation, NLRP3 inhibitors, Obesity, Ventyx Biosciences, VTX3232, VTX958

Eli Lilly; Lilly; Ventyx Biosciences; InduPro; inflammatory diseases; oncology; NLRP3 inhibitors; tamuzimod; VTX2735; VTX3232; VTX958; autoimmune; obesity; cardiometabolic; neuroinflammation; M&A; biotech deal; cancer immunotherapy

Lilly to acquire Ventyx Biosciences for ~$1.2B to add oral NLRP3 and other inflammatory drugs

2 weeks ago talkbio0Tagged Acquisition, Autoimmune Diseases, cardiometabolic, Eli, Eli Lilly, Inflammatory disorder, Neuroinflammation, NLRP3 inhibitors, oral therapies, Ventyx Biosciences

Eli Lilly; Ventyx Biosciences; $1.2 billion; acquisition; NLRP3 inhibitors; VTX3232; VTX2735; inflammatory diseases; oral therapies; cardiometabolic; neuroinflammation; autoimmune diseases

Ventus Therapeutics Continues Phase 2a Trial of VENT-02 NLRP3 Inhibitor in Parkinson’s Disease; No Indication of Program Halt

3 months ago talkbio0Tagged Biological Markers, Clinical Development, Neuroinflammation, NLRP3 inhibitor, Parkinson 's disease, Phase 2a Trial, VENT-02, Ventus Therapeutics

Ventus Therapeutics; VENT-02; NLRP3 inhibitor; Phase 2a trial; Parkinson’s disease; clinical development; neuroinflammation; biomarkers

“Continuum Biologics’ PIPE-791 Advances with Johnson & Johnson Partnership in Initial Public Offering (IPO)”

2 years ago talkbio0Tagged Biological Factors, Continuum, Demyelinating Diseases, IPO, Johnson & Johnson, LPAR1 antagonist, LPAR1 gene, Multiple Sclerosis, Neuroinflammation, PIPE-791, Public Offering, Receptors, Lysophosphatidic Acid

Continuum Biologics, PIPE-791, Johnson & Johnson partnership, Initial Public Offering (IPO), Multiple sclerosis, Demyelinating diseases, Neuroinflammation, LPAR1 antagonist, Lysophosphatidic acid receptor Edg-2 antagonist